Risk assessment of esophageal adenocarcinoma using γ-H2AX assay

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1797-1804

  Xu, Enping ^a,b   Gong, Yilei ^a   Gu, Jian ^a   Jie, Lin ^a   Ajani, Jaffer A ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX;

ADULT; AGE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING;

ADENOCARCINOMA; CASE-CONTROL STUDIES; DNA BREAKS, DOUBLE-STRANDED; ESOPHAGEAL NEOPLASMS; FEMALE; HISTONES; HUMANS; LASER SCANNING CYTOMETRY; LYMPHOCYTES; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 84886426448     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0485     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54 Suppl 1:i1-5.
3. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84.
4. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009;373: 850-61.
5. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002;122:588-90.
6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349: 2241-52.
7. Koch TR. The changing face of esophageal malignancy. Curr Gastroenterol Rep 2003;5:187-91.
8. Wu X, Gu J, Spitz MR. Mutagen sensitivity: a genetic predisposition factor for cancer. Cancer Res 2007;67:3493-5.
9. Hsu TC, Spitz MR, Schantz SP. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1991;1:83-9.
10. Wu X, Lin J, Etzel CJ, Dong Q, Gorlova OY, Zhang Q, et al. Interplay between mutagen sensitivity and epidemiological factors in modulating lung cancer risk. Int J Cancer 2007;120:2687-95.
11. Zheng YL, Loffredo CA, Yu Z, Jones RT, Krasna MJ, Alberg AJ, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
12. Gu J, Horikawa Y, Chen M, Dinney CP, Wu X. Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2445-50.
13. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.
14. Mills KD, Ferguson DO, Alt FW. The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev 2003;194:77-95.
15. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma- H2AX antibody. Radiat Res 2002;158:486-92.
16. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002; 12:162-9.
17. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
18. Firsanov DV, Solovjeva LV, Svetlova MP. H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues. Clin Epigenetics 2011;2:283-97.
19. Mah LJ, El-Osta A, Karagiannis TC. GammaH2AX as a molecular marker of aging and disease. Epigenetics 2010;5:129-36.
20. Simm A, Johnson TE. Biomarkers of ageing: a challenge for the future. Exp Gerontol 2010;45:731-2.
21. Andrievski A, Wilkins RC. The response of gamma-H2AX in human lymphocytes and lymphocytes subsets measured in whole blood cultures. Int J Radiat Biol 2009;85:369-76.
22. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM , et al. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat 2012; 132:1147-55.
23. Shao L, Lin J, Huang M, Ajani JA, Wu X Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer 2005;44:415-22.
24. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, et al. Genetic instability in bladder cancer assessed by comet assay. J Natl Cancer Inst 2003;95:540-7.
25. Shen H, Spitz MR, Qiao Y, Guo Z,WangLE, Bosken CH, et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int J Cancer 2003;107:84-8.
26. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204.
27. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000;405:697-700.
28. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010;10:4.
29. Jeggo PA, Lobrich M. DNA double-strand breaks: their cellular and clinical impact? Oncogene 2007;26:7717-9.
30. Colleu-Durel S, Guitton N, Nourgalieva K, Legue F, Leveque J, Danic B, et al. Alkaline single-cell gel electrophoresis (comet assay): a simple technique to show genomic instability in sporadic breast cancer. Eur J Cancer 2004;40:445-51.
31. Wang J, Delgado DA, Deen DF. Use of pulsed-field gel electrophoresis to investigate factors influencing the measurement of DNA doublestrand breaks in human brain tumour specimens. Int J Radiat Biol 1995;67:153-60.
32. Berwick M, Vineis P. Markers ofDNArepair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92: 874-97.
33. Hamasaki K, Imai K, Nakachi K, Takahashi N, Kodama Y, Kusunoki Y. Short-term culture and gammaH2AX flow cytometry determine differences in individual radiosensitivity in human peripheral T lymphocytes. Environ Mol Mutagen 2007;48:38-47.
34. Nakamura AJ, Redon CE, Sedelnikova OA. Where did they come from? The origin of endogenous gamma-H2AX foci in tumor cells. Cell Cycle 2009;8:2324.
35. Yu T, MacPhail SH, Banath JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair 2006;5:935-46.
36. Warters RL, Adamson PJ, Pond CD, Leachman SA. Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol 2005;124:807-17.
37. Cloos J, Nieuwenhuis EJ, Boomsma DI, Kuik DJ, van der Sterre ML, Arwert F, et al. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 1999;91:1125-30.
38. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? Am J Hum Genet 1999;65:784-94.
39. WuX, Spitz MR, Amos CI, Lin J, Shao L, Gu J, et al. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 2006; 66:5993-6.